Literature DB >> 26587330

CAR-T cells are serial killers.

Alexander J Davenport1, Misty R Jenkins2, David S Ritchie1, H Miles Prince3, Joseph A Trapani2, Michael H Kershaw2, Phillip K Darcy2, Paul J Neeson2.   

Abstract

Chimeric antigen receptor (CAR) T cells have enjoyed unprecedented clinical success against haematological malignancies in recent years. However, several aspects of CAR T cell biology remain unknown. We recently compared CAR and T cell receptor (TCR)-based killing in the same effector cell and showed that CAR T cells can not only efficiently kill single tumor targets, they can also kill multiple tumor targets in a sequential manner. Single and serial killing events were not sustained long term due to CAR down-regulation after 20 hours.

Entities:  

Keywords:  CAR; T cell therapy; serial killing

Year:  2015        PMID： 26587330      PMCID： PMC4635863          DOI： 10.1080/2162402X.2015.1053684

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  8 in total

1.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack.

Authors:  Jamie A Lopez; Olivia Susanto; Misty R Jenkins; Natalya Lukoyanova; Vivien R Sutton; Ruby H P Law; Angus Johnston; Catherina H Bird; Phillip I Bird; James C Whisstock; Joseph A Trapani; Helen R Saibil; Ilia Voskoboinik
Journal:  Blood       Date:  2013-02-01       Impact factor: 22.113

Review 3.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

4.  CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells.

Authors:  Alexander J Davenport; Misty R Jenkins; Ryan S Cross; Carmen S Yong; H Miles Prince; David S Ritchie; Joseph A Trapani; Michael H Kershaw; Phillip K Darcy; Paul J Neeson
Journal:  Cancer Immunol Res       Date:  2015-02-24       Impact factor: 11.151

5.  Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells.

Authors:  Ivan Liadi; Harjeet Singh; Gabrielle Romain; Nicolas Rey-Villamizar; Amine Merouane; Jay R T Adolacion; Partow Kebriaei; Helen Huls; Peng Qiu; Badrinath Roysam; Laurence J N Cooper; Navin Varadarajan
Journal:  Cancer Immunol Res       Date:  2015-02-24       Impact factor: 11.151

6.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

7.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Authors:  Martin A Pule; Barbara Savoldo; G Doug Myers; Claudia Rossig; Heidi V Russell; Gianpietro Dotti; M Helen Huls; Enli Liu; Adrian P Gee; Zhuyong Mei; Eric Yvon; Heidi L Weiss; Hao Liu; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Nat Med       Date:  2008-11-02       Impact factor: 53.440

Review 8.  CAR T cells for solid tumors: armed and ready to go?

Authors:  Sunitha Kakarla; Stephen Gottschalk
Journal:  Cancer J       Date:  2014 Mar-Apr       Impact factor: 3.360
  8 in total
  7 in total

Review 1.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

2.  CARs on a highway with roadblocks.

Authors:  Lorenzo Galluzzi; Peter Martin
Journal:  Oncoimmunology       Date:  2017-10-11       Impact factor: 8.110

3.  In vitro immunotherapy potency assays using real-time cell analysis.

Authors:  Fabio Cerignoli; Yama A Abassi; Brandon J Lamarche; Garret Guenther; David Santa Ana; Diana Guimet; Wen Zhang; Jing Zhang; Biao Xi
Journal:  PLoS One       Date:  2018-03-02       Impact factor: 3.240

Review 4.  Are ovarian cancer stem cells the target for innovative immunotherapy?

Authors:  Liang Wang; Tianmin Xu; Manhua Cui
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

5.  Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer.

Authors:  Haibo Han; Shanshan Wang; Ying Hu; Zhaowei Li; Wei Yang; Yunwei Lv; Limin Wang; Lianhai Zhang; Jiafu Ji
Journal:  Oncol Lett       Date:  2018-03-13       Impact factor: 2.967

Review 6.  Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.

Authors:  In-Young Jung; Jungmin Lee
Journal:  Mol Cells       Date:  2018-08-14       Impact factor: 5.034

7.  A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.

Authors:  Claudia Arndt; Anja Feldmann; Stefanie Koristka; Martin Schäfer; Ralf Bergmann; Nicola Mitwasi; Nicole Berndt; Dominik Bachmann; Alexandra Kegler; Marc Schmitz; Edinson Puentes-Cala; Javier Andrés Soto; Gerhard Ehninger; Jens Pietzsch; Christos Liolios; Gerd Wunderlich; Jörg Kotzerke; Klaus Kopka; Michael Bachmann
Journal:  Oncoimmunology       Date:  2019-09-07       Impact factor: 8.110
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.